



Ideas2Impact Bootcamp

“Creating a Value Proposition for your Research”

Cynthia Sundell, PhD

Senior Dir Life Sciences, Petit Institute for Bioengineering and Biosciences; Principal Georgia Tech VentureLab; Co-ILO Center for Cell Manufacturing Technologies

- Learn how to talk about the value proposition of your research to a general audience
- Learn how “stakeholder discovery” can help refine your research efforts and lead to commercialization opportunities
- Gain communication skills relevant to 3MT and PPC
- Instill a commercialization mindset
- Actively engage all trainees and members of the CMaT Innovation Ecosystem (especially during Covid19)
- Serve as an “on-ramp” to I-Corps

- Two lectures (1 hr each)
 - “Communicating the Value Proposition of your Research”
 - “Talking to Humans – Importance of Stakeholder Discovery”
- Research Impact Statement Workshop (90 mins)
 - Students submit a Research Impact Statement (RIS) prior to workshop
 - 2 min presentation
 - Mentors (2-3 from IE) provide feedback
- Post bootcamp (optional)
 - Stakeholder discovery interviews
 - Revised RIS
 - Presentation at Weekly research meetings

- Held virtually at CMaT Annual Retreat (Bluejeans platform)
- Mandatory for CMaT Graduate Students, optional for Post Docs
- Lectures open to all CMaT (Bluejeans Events)
- Research Impact Statement (RIS) Workshop with 8 simultaneous breakout sessions
 - Trainees submit RIS before workshop
 - Breakout groups
 - 2 mins RIS presentations
 - 4 min feedback from mentors
 - Moderators advance slides and keeps clock
- Participation: 52 trainees, 24 mentors, 8 moderators from across CMaT IE

Title

Name

- Research Impact Statement:
- A concise statement that consists of three parts:
 - 1) What is the expected outcome(s) of your research
 - 2) Who are the stakeholders that care about your research outcome(s)
 - 3) Why will the stakeholders care
- Example: Real-time process monitoring of bioreactor lactate levels for cell therapy manufacturers that reduces manufacturing costs 3-fold compared with current methods.

A variable lymphocyte receptor-based CAR T cell for specific treatment of multiple myeloma and other plasma cell malignancies

Sam McCachren

Novel chimeric antigen receptors allowing more specific targeting of malignant plasma cells for improved treatment for multiple myeloma patients will provide a new approach to targeting a currently incurable cancer.

NMR Metabolomics for Improving Immunotherapies

Max Colonna

Identification of small molecule CQAs for CAR-T-cell therapy developers to maximize potency and efficacy of cell products.

Modulating MSC Proliferation and Secretion for Treating Inflammatory Diseases

Gilad Doron

Culture strategies that enable the production of highly-secretory mesenchymal stromal cells (MSCs) can be used by cell therapy manufacturers to increase resulting cell potency and improve manufacturing efficiency by 2-fold versus current methods.

CRISPR Generated CAR NK Cell Therapy for Neuroblastoma

Keerthana Shankar

Development of a CRISPR edited CAR NK product for immunotherapy manufacturers that eliminates the manufacturing risks and high costs associated with virally edited cell products in addition to addressing limitations with current T cell therapies.

- Stakeholder Discovery – hold 5-10 interviews to test RIS hypothesis
- Create modified RIS based on stakeholder feedback
 - This is an ongoing process
- Present modified RIS at CMaT weekly research meetings
- Modify research as appropriate

- Outputs
 - Research Impact Statements
 - Compendium of RISs
- Outcomes
 - Better ability to succinctly communicate research value proposition
 - Value of stakeholder/customer discovery
 - New research ideas
 - Networking/ industry engagement
 - Commercialization opportunities

We would love your feedback!

- In the spirit of continuous improvement we would like to know:
 - Thoughts on how to improve/expand offerings
 - Relevance to your ERC

Thank you!!